GlassScriptPhysician profile
Colleen R Eicher
NPI 1821766270
$2,900.63
in general payments reported to CMS, 2019-2025
41 companies · $1,408 in 2025
The $1,408 reported for 2025 was more than what 92% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $127 · 2023: $330 · 2024: $1,036 · 2025: $1,408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,683 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,683.39 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $359.98 | 2022-2025 | Tivdak, Epkinly |
| Merck Sharp & Dohme LLC | $328.93 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $295.32 | 2024-2025 | Enhertu, Injectafer, Vanflyta |
| Eisai INC. | $250.34 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $118.94 | 2024-2025 | |
| Astellas Pharma US INC | $112.88 | 2024-2025 | Vyloy, Veozah, Xospata |
| Abbvie INC. | $98.10 | 2024-2025 | |
| Janssen Biotech, INC. | $97.15 | 2024-2025 | Rybrevant, Darzalex, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $90.46 | 2024-2025 | Fruzaqla, Alunbrig, Iclusig |
| Pharmacosmos Therapeutics INC. | $85.09 | 2024-2025 | Monoferric |
| Lilly USA, LLC | $74.89 | 2024 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $74.79 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $69.22 | 2024-2025 | Calquence, Lynparza |
| Stemline Therapeutics INC. | $59.83 | 2024-2025 | Elzonris |
| Genentech USA, INC. | $58.25 | 2024-2025 | Itovebi, Venclexta |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $54.43 | 2022-2023 | Jemperli |
| Gilead Sciences, INC. | $49.00 | 2025 | Trodelvy |
| Caris Mpi, INC. | $42.09 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $40.04 | 2024-2025 | Myfembree, Orgovyx |
| Emd Serono, INC. | $39.94 | 2024-2025 | |
| Celgene Corporation | $39.09 | 2025 | Reblozyl |
| Genzyme Corporation | $37.04 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $32.84 | 2025 | |
| Blueprint Medicines Corporation | $32.03 | 2025 | Ayvakit |
| Puma Biotechnology, INC. | $29.42 | 2024-2025 | |
| Tersera Therapeutics LLC | $28.24 | 2024 | Zoladex |
| Incyte Corporation | $26.88 | 2025 | Zynyz, Monjuvi |
| Invivyd INC | $26.61 | 2025 | Pemgarda |
| Pfizer INC. | $25.74 | 2025 | |
| Myriad Genetic Laboratories, INC. | $21.13 | 2025 | Myrisk |
| E.R. Squibb & Sons, L.L.C. | $20.54 | 2025 | Opdivo |
| Kite Pharma, INC. | $19.98 | 2025 | Yescarta |
| Sobi, INC | $19.94 | 2024 | |
| Legend Biotech USA INC. | $19.79 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $19.62 | 2025 | Qinlock, Tgct |
| Octapharma USA, INC. | $19.48 | 2024 | Panzyga |
| Immunogen, INC. | $17.14 | 2023 | Elahere |
| Iovance Biotherapeutics, INC. | $16.89 | 2024 | Amtagvi |
| Janssen Scientific Affairs, LLC | $16.48 | 2025 | Darzalex, Tecvayli, Talvey |
| Regeneron Healthcare Solutions, INC. | $16.05 | 2025 | Libtayo |
| Fresenius Kabi USA, LLC | $16.03 | 2025 | Stimufend |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Eicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.